Responses
Psoriatic arthritis
Original article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Compose a Response to This Article
Other responses
No responses have been published for this article.